Amphastar Pharmaceuticals

Aging Population Will Expand Markets Despite Intense Rivalry

AnalystHighTarget

Not Invested

Consensus Narrative from 6 Analysts

Published

04 May 25

Updated

20 Aug 25

AnalystHighTarget's Fair Value

US$38.00

21.5% undervalued

20 Aug

US$29.83

-38.0%

0.2%

-38.0%

0.2%

Author's Valuation

US$38.0

21.5% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on07 May 25
Fair value Decreased 13%

AnalystHighTarget made no meaningful changes to valuation assumptions.

AnalystHighTarget Fair Value

US$38.0

21.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.96%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$140.35m

Earnings '28

13.84x

PE Ratio '28

US$1.94b

Market Cap '28

US$1.94b

Market Cap '28

42.04m

No. shares '28

US$46.21

Share Price '28

US$46.21 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$37.96

Fair Value '25

Aging Population Will Expand Markets Despite Intense Rivalry

Shared on07 May 25Fair value Decreased 13%

Shared on07 May 25
Fair value Decreased 13%